ストックスクリーナーアプリを入手
40.40
2.11%
-1.0376
Avidity Biosciences Inc (RNA) 最新ニュース
Roth Capital Initiates Coverage on RNA with a 'Buy' Rating | RNA Stock News - GuruFocus
Decliners Report: Can Avidity Biosciences Inc continue delivering strong returnsMarket Risk Analysis & Free Risk Controlled Daily Trade Plans - خودرو بانک
Roth Capital Partners Initiates Avidity Biosciences at Buy - MarketScreener
Voya Investment Management LLC Has $9.81 Million Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Trading Down 5.3%Here's What Happened - MarketBeat
Bank of America Issues Positive Forecast for Avidity Biosciences (NASDAQ:RNA) Stock Price - MarketBeat
Ark, Atom file to go public in Hong Kong; Aptevo’s stock rallies on AML data - Endpoints News
MACD Signal: Is Avidity Biosciences Inc part of any major index2025 Trading Recap & AI Based Trade Execution Alerts - خودرو بانک
Avidity Biosciences prices $600M stock offering - MSN
Will Avidity Biosciences Inc announce a stock splitJuly 2025 Movers & Low Risk High Reward Trade Ideas - خودرو بانک
Trading Recap: What is the dividend yield of USGOW2025 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - خودرو بانک
Volume Report: How does Avidity Biosciences Inc compare to its peersIPO Watch & Verified Chart Pattern Trade Signals - خودرو بانک
Dow Update: What is Avidity Biosciences Incs book value per shareEarnings Risk Report & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Avidity Biosciences closes $690 million public offering By Investing.com - Investing.com Canada
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - StreetInsider
Avidity Biosciences closes $690 million public offering - Investing.com
Avidity Biosciences Closes $690 Million Share Offering - MarketScreener
Volume Summary: Can Avidity Biosciences Inc outperform in the next rallyJuly 2025 Catalysts & Safe Entry Zone Tips - خودرو بانک
Avidity Biosciences stock price target raised to $87 by H.C. Wainwright - Investing.com Canada
Moving Averages: Is Avidity Biosciences Inc part of any major index2025 Earnings Surprises & High Return Trade Guides - خودرو بانک
Institution Moves: Can Avidity Biosciences Inc outperform in the next rallyLayoff News & Free Safe Capital Growth Stock Tips - خودرو بانک
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Profit Review: Is Avidity Biosciences Inc. trading at a discount2025 AllTime Highs & Verified High Yield Trade Plans - خودرو بانک
Rhumbline Advisers Has $4.86 Million Stock Position in Avidity Biosciences, Inc. $RNA - MarketBeat
Insider Selling: Avidity Biosciences (NASDAQ:RNA) Director Sells 29,500 Shares of Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Shares Gap Up on Analyst Upgrade - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Given New $87.00 Price Target at HC Wainwright - MarketBeat
Avidity Biosciences Announces Major Stock Offering - MSN
Avidity Biosciences (NASDAQ:RNA) Shares Gap DownWhat's Next? - MarketBeat
Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating - Yahoo Finance
Avidity Biosciences (RNA) Is Down 11.2% After $600 Million Equity Raise to Fund Late-Stage Pipeline - Yahoo Finance
Avidity Biosciences launches $500M proposed public offering - MSN
Wilson Sonsini Advises Avidity Biosciences on Patent Matters Related to $600 Million Upsized Public Offering - Wilson Sonsini
Avidity Biosciences files for offering of 15 million shares of common stockSEC filing - MarketScreener
Avidity Biosciences stock price target raised to $65 at BofA Securities - Investing.com Australia
Latham & Watkins Advises Avidity Biosciences on Upsized US$600 Million Public Offering of Common Stock - Latham & Watkins LLP
Avidity Biosciences (NASDAQ:RNA) Price Target Raised to $65.00 at Needham & Company LLC - MarketBeat
Avidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Avidity’s offering follows reversal of Duchenne disease progression - BioWorld MedTech
A new biotech fund in the Middle East; Xspray preps for FDA decision on Dasynoc - Endpoints News
HC Wainwright Adjusts Avidity Biosciences Price Target to $87 From $68, Maintains Buy Rating - MarketScreener
Avidity Biosciences reports data from DMD treatment trials - MSN
Avidity Biosciences price target raised to $87 from $68 at H.C. Wainwright - TipRanks
Avidity Biosciences Prices $600 Million Equity Offering - MarketScreener
Avidity Biosciences prices upsized public offering at $600 million By Investing.com - Investing.com South Africa
Avidity Biosciences prices upsized public offering at $600 million - Investing.com India
Alyeska Investment Group L.P. Has $2.95 Million Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences prices upsized public offering at $40 per share - MarketScreener
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - Nasdaq
Share Sales Send Small Biotech Stocks To New Lows - Finimize
Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota - Seeking Alpha
Top Midday Decliners - MarketScreener
Raymond James Sticks to Its Buy Rating for Avidity Biosciences (RNA) - The Globe and Mail
Avidity Biosciences: Promising Outlook for DMD Treatment with Del-Zota and Platform Expansion - TipRanks
0.69%
0.61%
大文字化:
|
ボリューム (24 時間):